-
公开(公告)号：US20080221011A1
公开(公告)日：2008-09-11
申请号：US11821370
申请日：2007-06-21
CPC分类号： C07K14/705 , A61K38/00 , C07K14/47 , C07K14/70596 , C07K2319/00
摘要： The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
摘要翻译： 本发明提供包含CR2部分的CR2-FH分子，其包含CR2蛋白或其片段和包含因子H蛋白或其片段的FH部分和包含CR2-FH分子的药物组合物。 还提供了使用组合物治疗涉及替代补体途径的疾病的方法，例如年龄相关性黄斑变性，类风湿性关节炎和缺血再灌注。
-
公开(公告)号：US08569225B2
公开(公告)日：2013-10-29
申请号：US12782526
申请日：2010-05-18
CPC分类号： C07K14/705 , A61K38/00 , C07K14/47 , C07K14/70596 , C07K2319/00
摘要： The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
-
公开(公告)号：US07759304B2
公开(公告)日：2010-07-20
申请号：US11821370
申请日：2007-06-21
IPC分类号： C07K14/00
CPC分类号： C07K14/705 , A61K38/00 , C07K14/47 , C07K14/70596 , C07K2319/00
摘要： The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
摘要翻译： 本发明提供包含CR2部分的CR2-FH分子，其包含CR2蛋白或其片段和包含因子H蛋白或其片段的FH部分和包含CR2-FH分子的药物组合物。 还提供了使用组合物治疗涉及替代补体途径的疾病的方法，例如年龄相关性黄斑变性，类风湿性关节炎和缺血再灌注。
-
公开(公告)号：US08540997B2
公开(公告)日：2013-09-24
申请号：US13162434
申请日：2011-06-16
IPC分类号： A61K39/00
CPC分类号： C07K14/70596 , A61K38/00 , C07K14/705 , C07K16/2896 , C07K2319/00
摘要： Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
摘要翻译： 补体系统的调节代表了与补体激活相关的许多病理状况的治疗方式。 在制备靶向补体活化和疾病部位的补体抑制剂的策略中，公开了包含与补体受体（CR）2连接的补体抑制剂的组合物。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。
-
公开(公告)号：US08007804B2
公开(公告)日：2011-08-30
申请号：US10534772
申请日：2003-11-13
CPC分类号： C07K14/70596 , A61K38/00 , C07K14/705 , C07K16/2896 , C07K2319/00
摘要： Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
摘要翻译： 补体系统的调节代表了与补体激活相关的许多病理状况的治疗方式。 在制备靶向补体活化和疾病部位的补体抑制剂的策略中，公开了包含与补体受体（CR）2连接的补体抑制剂的组合物。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。
-
公开(公告)号：US09815890B2
公开(公告)日：2017-11-14
申请号：US13805522
申请日：2011-06-22
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , C07K14/47
CPC分类号： C07K16/18 , C07K14/472 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.
-
公开(公告)号：US20120014952A1
公开(公告)日：2012-01-19
申请号：US13162479
申请日：2011-06-16
IPC分类号： A61K39/395 , C07K14/705 , A61K38/17 , A61P29/00 , A61P31/04 , A61P31/10 , A61P33/00 , A61P35/00 , C07K19/00 , A61P31/12
CPC分类号： C07K14/70596 , A61K38/00 , C07K14/705 , C07K16/2896 , C07K2319/00
摘要： Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
-
8.发明申请公开(公告)号：US20060292141A1
公开(公告)日：2006-12-28
申请号：US11441828
申请日：2006-05-26
IPC分类号： A61K39/395
CPC分类号： C07K16/42 , A61K2039/505 , C07K16/18 , C07K2317/76 , C07K2319/30
摘要： Disclosed is the use of agents and compositions that selectively inhibit the alternative complement pathway for the inhibiting or treating physiological damage resulting from traumatic brain injury (TBI), spinal cord injury (SCI), or related conditions. Preferred reagents for use in inhibition of damage resulting from TBI or SCI include those that inhibit factor B, with anti-factor B antibodies representing a particularly preferred agent.
摘要翻译： 公开了使用选择性抑制替代补体途径用于抑制或治疗由创伤性脑损伤（TBI），脊髓损伤（SCI）或相关病症引起的生理损伤的药剂和组合物。 用于抑制由TBI或SCI引起的损伤的优选试剂包括抑制因子B的那些，抗因子B抗体代表特别优选的药剂。
-
9.发明申请PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION INJURY AND RELATED CONDITIONS 审中-公开预防和治疗ISCHEMIA-REPERFUSION伤害及相关条件公开(公告)号：US20110014270A1
公开(公告)日：2011-01-20
申请号：US12294870
申请日：2007-03-27
IPC分类号： A61K9/127 , A61K38/16 , A61K39/395 , C07K16/00 , C07K14/00 , A61P9/10 , A61P13/12 , A61P25/00 , A61P37/06
CPC分类号： A61K38/1709 , A61K9/0019 , A61K9/127 , A61K9/1272 , A61K31/685 , C07K16/18
摘要： Disclosed are Lipids, Annexin, and Lipid-Annexin Complexes for Use in the Prevention and/or Treatment of Ischemia-Reperfusion injury and reperfusion injury associated with a variety of diseases and conditions. Also disclosed are therapeutic targets and compositions for the prevention and treatment of ischemia-reperfusion injury and diseases and conditions associated with ischemia-reperfusion injury.
摘要翻译： 公开了用于预防和/或治疗与各种疾病和病症相关的缺血 - 再灌注损伤和再灌注损伤的脂质，膜联蛋白和脂质 - 膜联蛋白复合物。 还公开了用于预防和治疗缺血再灌注损伤以及与缺血 - 再灌注损伤相关的疾病和病症的治疗靶标和组合物。
-
公开(公告)号：US20080267980A1
公开(公告)日：2008-10-30
申请号：US10534772
申请日：2003-11-13
CPC分类号： C07K14/70596 , A61K38/00 , C07K14/705 , C07K16/2896 , C07K2319/00
摘要： Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
摘要翻译： 补体系统的调节代表了与补体激活相关的许多病理状况的治疗方式。 在制备靶向补体活化和疾病部位的补体抑制剂的策略中，公开了包含与补体受体（CR）2连接的补体抑制剂的组合物。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.023 秒)
